vs
KRONOS WORLDWIDE INC（KRO）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
KRONOS WORLDWIDE INC的季度营收约是Orthofix Medical Inc.的1.9倍（$418.3M vs $219.9M），Orthofix Medical Inc.净利率更高（-1.0% vs -19.8%，领先18.8%），Orthofix Medical Inc.同比增速更快（2.0% vs -1.1%），KRONOS WORLDWIDE INC自由现金流更多（$81.9M vs $16.8M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs -6.5%）
克罗诺斯全球（原克罗诺斯公司）是一家美国跨国企业，总部位于美国马萨诸塞州洛厄尔，专注于提供劳动力管理与人力资本管理云服务，在全球拥有超过6000名员工，是该领域知名的服务提供商。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
KRO vs OFIX — 直观对比
营收规模更大
KRO
是对方的1.9倍
$219.9M
营收增速更快
OFIX
高出3.1%
-1.1%
净利率更高
OFIX
高出18.8%
-19.8%
自由现金流更多
KRO
多$65.1M
$16.8M
两年增速更快
OFIX
近两年复合增速
-6.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $418.3M | $219.9M |
| 净利润 | $-82.8M | $-2.2M |
| 毛利率 | -0.9% | 71.1% |
| 营业利润率 | -15.1% | 0.2% |
| 净利率 | -19.8% | -1.0% |
| 营收同比 | -1.1% | 2.0% |
| 净利润同比 | -527.3% | 92.4% |
| 每股收益（稀释后） | $-0.72 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收KROOFIX
| Q4 25 | $418.3M | $219.9M | ||
| Q3 25 | $456.9M | $205.6M | ||
| Q2 25 | $494.4M | $203.1M | ||
| Q1 25 | $489.8M | $193.6M | ||
| Q4 24 | $423.1M | $215.7M | ||
| Q3 24 | $484.7M | $196.6M | ||
| Q2 24 | $500.5M | $198.6M | ||
| Q1 24 | $478.8M | $188.6M |
净利润KROOFIX
| Q4 25 | $-82.8M | $-2.2M | ||
| Q3 25 | $-37.0M | $-22.8M | ||
| Q2 25 | $-9.2M | $-14.1M | ||
| Q1 25 | $18.1M | $-53.1M | ||
| Q4 24 | $-13.2M | $-29.1M | ||
| Q3 24 | $71.8M | $-27.4M | ||
| Q2 24 | $19.5M | $-33.4M | ||
| Q1 24 | $8.1M | $-36.0M |
毛利率KROOFIX
| Q4 25 | -0.9% | 71.1% | ||
| Q3 25 | 10.3% | 72.2% | ||
| Q2 25 | 12.7% | 68.7% | ||
| Q1 25 | 21.8% | 62.8% | ||
| Q4 24 | 20.4% | 69.0% | ||
| Q3 24 | 20.9% | 68.7% | ||
| Q2 24 | 20.0% | 67.8% | ||
| Q1 24 | 14.9% | 67.5% |
营业利润率KROOFIX
| Q4 25 | -15.1% | 0.2% | ||
| Q3 25 | -4.2% | -8.3% | ||
| Q2 25 | 1.5% | -7.9% | ||
| Q1 25 | 7.8% | -25.2% | ||
| Q4 24 | 6.8% | -5.3% | ||
| Q3 24 | 8.0% | -9.6% | ||
| Q2 24 | 7.2% | -12.5% | ||
| Q1 24 | 4.1% | -15.6% |
净利率KROOFIX
| Q4 25 | -19.8% | -1.0% | ||
| Q3 25 | -8.1% | -11.1% | ||
| Q2 25 | -1.9% | -6.9% | ||
| Q1 25 | 3.7% | -27.4% | ||
| Q4 24 | -3.1% | -13.5% | ||
| Q3 24 | 14.8% | -13.9% | ||
| Q2 24 | 3.9% | -16.8% | ||
| Q1 24 | 1.7% | -19.1% |
每股收益（稀释后）KROOFIX
| Q4 25 | $-0.72 | $-0.05 | ||
| Q3 25 | $-0.32 | $-0.57 | ||
| Q2 25 | $-0.08 | $-0.36 | ||
| Q1 25 | $0.16 | $-1.35 | ||
| Q4 24 | $-0.11 | $-0.76 | ||
| Q3 24 | $0.62 | $-0.71 | ||
| Q2 24 | $0.17 | $-0.88 | ||
| Q1 24 | $0.07 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $33.2M | $82.0M |
| 总债务越低越好 | $557.4M | — |
| 股东权益账面价值 | $751.1M | $450.0M |
| 总资产 | $1.8B | $850.6M |
| 负债/权益比越低杠杆越低 | 0.74× | — |
8季度趋势，按日历期对齐
现金及短期投资KROOFIX
| Q4 25 | $33.2M | $82.0M | ||
| Q3 25 | $27.7M | $62.9M | ||
| Q2 25 | $18.9M | $65.6M | ||
| Q1 25 | $20.5M | $58.0M | ||
| Q4 24 | $106.7M | $83.2M | ||
| Q3 24 | $94.8M | $30.1M | ||
| Q2 24 | $133.8M | $26.4M | ||
| Q1 24 | $120.7M | $27.0M |
总债务KROOFIX
| Q4 25 | $557.4M | — | ||
| Q3 25 | $626.2M | $157.2M | ||
| Q2 25 | $589.3M | $157.0M | ||
| Q1 25 | $557.2M | $156.9M | ||
| Q4 24 | $507.4M | $157.0M | ||
| Q3 24 | $554.3M | $118.5M | ||
| Q2 24 | $423.7M | $118.0M | ||
| Q1 24 | $426.9M | $118.2M |
股东权益KROOFIX
| Q4 25 | $751.1M | $450.0M | ||
| Q3 25 | $804.7M | $442.5M | ||
| Q2 25 | $846.8M | $458.3M | ||
| Q1 25 | $847.0M | $458.3M | ||
| Q4 24 | $817.0M | $503.1M | ||
| Q3 24 | $847.4M | $525.9M | ||
| Q2 24 | $774.6M | $546.0M | ||
| Q1 24 | $774.4M | $570.3M |
总资产KROOFIX
| Q4 25 | $1.8B | $850.6M | ||
| Q3 25 | $1.9B | $832.6M | ||
| Q2 25 | $1.9B | $837.2M | ||
| Q1 25 | $1.9B | $823.1M | ||
| Q4 24 | $1.9B | $893.3M | ||
| Q3 24 | $1.9B | $867.9M | ||
| Q2 24 | $1.7B | $882.0M | ||
| Q1 24 | $1.7B | $906.0M |
负债/权益比KROOFIX
| Q4 25 | 0.74× | — | ||
| Q3 25 | 0.78× | 0.36× | ||
| Q2 25 | 0.70× | 0.34× | ||
| Q1 25 | 0.66× | 0.34× | ||
| Q4 24 | 0.62× | 0.31× | ||
| Q3 24 | 0.65× | 0.23× | ||
| Q2 24 | 0.55× | 0.22× | ||
| Q1 24 | 0.55× | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $92.1M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $81.9M | $16.8M |
| 自由现金流率自由现金流/营收 | 19.6% | 7.6% |
| 资本支出强度资本支出/营收 | 2.4% | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-40.4M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流KROOFIX
| Q4 25 | $92.1M | $27.7M | ||
| Q3 25 | $-7.9M | $12.4M | ||
| Q2 25 | $20.7M | $11.6M | ||
| Q1 25 | $-102.4M | $-18.4M | ||
| Q4 24 | $49.3M | $23.7M | ||
| Q3 24 | $28.3M | $11.7M | ||
| Q2 24 | $38.2M | $9.0M | ||
| Q1 24 | $-43.3M | $-18.6M |
自由现金流KROOFIX
| Q4 25 | $81.9M | $16.8M | ||
| Q3 25 | $-17.4M | $2.5M | ||
| Q2 25 | $9.5M | $4.5M | ||
| Q1 25 | $-114.4M | $-25.1M | ||
| Q4 24 | $37.0M | $15.2M | ||
| Q3 24 | $19.2M | $6.3M | ||
| Q2 24 | $34.8M | $-360.0K | ||
| Q1 24 | $-48.0M | $-29.1M |
自由现金流率KROOFIX
| Q4 25 | 19.6% | 7.6% | ||
| Q3 25 | -3.8% | 1.2% | ||
| Q2 25 | 1.9% | 2.2% | ||
| Q1 25 | -23.4% | -13.0% | ||
| Q4 24 | 8.7% | 7.0% | ||
| Q3 24 | 4.0% | 3.2% | ||
| Q2 24 | 7.0% | -0.2% | ||
| Q1 24 | -10.0% | -15.4% |
资本支出强度KROOFIX
| Q4 25 | 2.4% | 4.9% | ||
| Q3 25 | 2.1% | 4.8% | ||
| Q2 25 | 2.3% | 3.5% | ||
| Q1 25 | 2.4% | 3.5% | ||
| Q4 24 | 2.9% | 4.0% | ||
| Q3 24 | 1.9% | 2.7% | ||
| Q2 24 | 0.7% | 4.7% | ||
| Q1 24 | 1.0% | 5.6% |
现金转化率KROOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -5.66× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.39× | — | ||
| Q2 24 | 1.96× | — | ||
| Q1 24 | -5.35× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
KRO
暂无分部数据
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
